New treatment tested to tame rare, debilitating nerve disease
NCT ID NCT06724809
Summary
This study is testing a drug called eculizumab in Chinese adults with a rare autoimmune disease called Neuromyelitis Optica Spectrum Disorder (NMOSD). The main goal is to see if the drug can reduce the frequency of disease attacks (relapses) and slow disability progression. Researchers will also closely monitor the drug's safety and how the body processes it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Beijing, 100016, China
-
Research Site
Dongguan, 523059, China
-
Research Site
Jinan, 250012, China
-
Research Site
Shanghai, 200040, China
-
Research Site
Taiyuan, 030001, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
Conditions
Explore the condition pages connected to this study.